{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:13:46Z","timestamp":1792613626401,"version":"4.5.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Therapy-related myeloid neoplasms (tMN) develop after exposure to cytotoxic and radiation therapy, and due to their adverse prognosis, it is of paramount interest to identify patients at high risk. The presence of clonal hematopoiesis has been shown to increase the risk of developing tMN. The value of analyzing hematopoietic stem cells harvested at leukapheresis before autologous stem cell transplantation (ASCT) with next-generation sequencing and immunophenotyping represents potentially informative parameters that have yet to be discovered. We performed a nested case-control study to elucidate the association between clonal hematopoiesis, mobilization potential, and aberrant immunophenotype in leukapheresis products with the development of tMN after ASCT. A total of 36 patients with nonmyeloid disease who were diagnosed with tMN after treatment with ASCT were included as case subjects. Case subjects were identified from a cohort of 1130 patients treated with ASCT and matched with 36 control subjects who did not develop tMN after ASCT. Case subjects were significantly poorer mobilizers of CD34+ cells at leukapheresis (P = .016), indicating that these patients possess inferior bone marrow function. Both clonal hematopoiesis (odds ratio, 5.9; 95% confidence interval, 1.8-19.1; P = .003) and aberrant expression of CD7 (odds ratio, 6.6; 95% confidence interval, 1.6-26.2; P = .004) at the time of ASCT were associated with an increased risk of developing tMN after ASCT. In conclusion, clonal hematopoiesis, present at low variant allele frequencies, and aberrant CD7 expression on stem cells in leukapheresis products from patients with nonmyeloid hematologic cancer hold potential for the early identification of patients at high risk of developing tMN after ASCT.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019001157","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T16:20:02Z","timestamp":1583770802000},"page":"885-892","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":49,"title":["Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post\u2013autologous stem cell transplantation"],"prefix":"10.1182","volume":"4","author":[{"given":"Johannes Frasez","family":"Soerensen","sequence":"first","affiliation":[{"name":"Department of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anni","family":"Aggerholm","sequence":"first","affiliation":[{"name":"Department of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gitte Birk","family":"Kerndrup","sequence":"first","affiliation":[{"name":"Department of Pathology, Aarhus University Hospital, Aarhus, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus Celik","family":"Hansen","sequence":"first","affiliation":[{"name":"Department of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina Kathrine Lykke","family":"Ewald","sequence":"first","affiliation":[{"name":"Department of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Bill","sequence":"first","affiliation":[{"name":"Department of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene Hyldahl","family":"Ebbesen","sequence":"first","affiliation":[{"name":"Department of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina Agerbo","family":"Rosenberg","sequence":"first","affiliation":[{"name":"Department of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hokland","sequence":"first","affiliation":[{"name":"Department of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5089-3271","authenticated-orcid":false,"given":"Maja","family":"Ludvigsen","sequence":"first","affiliation":[{"name":"Department of Hematology and"},{"name":"Department of Clinical Medicine, Aarhus University, Aarhus, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Stidsholt Roug","sequence":"first","affiliation":[{"name":"Department of Hematology and"},{"name":"Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; and"},{"name":"Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,3,9]]},"reference":[{"issue":"20","key":"2020030912394192500_B1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2020030912394192500_B2","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/bmt.2017.52","article-title":"Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma","volume":"52","author":"Yamasaki","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"2020030912394192500_B3","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.leukres.2018.07.016","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma","volume":"74","author":"Radivoyevitch","year":"2018","journal-title":"Leuk Res"},{"key":"2020030912394192500_B4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.leukres.2018.07.013","article-title":"Incidence and survival of therapy related myeloid neoplasm in United States","volume":"71","author":"Guru Murthy","year":"2018","journal-title":"Leuk Res"},{"issue":"1","key":"2020030912394192500_B5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","article-title":"Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series","volume":"102","author":"Smith","year":"2003","journal-title":"Blood"},{"issue":"7","key":"2020030912394192500_B6","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","article-title":"The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML","volume":"117","author":"Kayser","year":"2011","journal-title":"Blood"},{"issue":"31","key":"2020030912394192500_B7","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study","volume":"33","author":"Granfeldt \u00d8stg\u00e5rd","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020030912394192500_B8","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.23908","article-title":"Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry","volume":"90","author":"Huleg\u00e5rdh","year":"2015","journal-title":"Am J Hematol"},{"issue":"12","key":"2020030912394192500_B9","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s00277-018-3462-y","article-title":"A monocentric retrospective study of 138 therapy-related myeloid neoplasms","volume":"97","author":"Claerhout","year":"2018","journal-title":"Ann Hematol"},{"issue":"1","key":"2020030912394192500_B10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"issue":"26","key":"2020030912394192500_B11","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"2020030912394192500_B12","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"14","key":"2020030912394192500_B13","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","article-title":"Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma","volume":"35","author":"Gibson","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020030912394192500_B14","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1470-2045(16)30627-1","article-title":"Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study","volume":"18","author":"Gillis","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"2020030912394192500_B15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2020030912394192500_B16","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","article-title":"Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"2020030912394192500_B17","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/j.celrep.2019.04.064","article-title":"Functional dominance of CHIP-mutated hematopoietic stem cells in patients undergoing autologous transplantation","volume":"27","author":"Ortmann","year":"2019","journal-title":"Cell Reports"},{"issue":"7714","key":"2020030912394192500_B18","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","article-title":"Prediction of acute myeloid leukaemia risk in healthy individuals","volume":"559","author":"Abelson","year":"2018","journal-title":"Nature"},{"issue":"1","key":"2020030912394192500_B19","doi-asserted-by":"crossref","first-page":"12484","DOI":"10.1038\/ncomms12484","article-title":"Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults","volume":"7","author":"Young","year":"2016","journal-title":"Nat Commun"},{"issue":"25","key":"2020030912394192500_B20","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical significance of somatic mutation in unexplained blood cytopenia","volume":"129","author":"Malcovati","year":"2017","journal-title":"Blood"},{"issue":"13","key":"2020030912394192500_B21","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"2020030912394192500_B22","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41591-018-0081-z","article-title":"Somatic mutations precede acute myeloid leukemia years before diagnosis","volume":"24","author":"Desai","year":"2018","journal-title":"Nat Med"},{"issue":"8","key":"2020030912394192500_B23","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.celrep.2015.02.005","article-title":"Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis","volume":"10","author":"McKerrell","year":"2015","journal-title":"Cell Reports"},{"issue":"3","key":"2020030912394192500_B24","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes","volume":"21","author":"Coombs","year":"2017","journal-title":"Cell Stem Cell"},{"issue":"8","key":"2020030912394192500_B25","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41375-018-0150-9","article-title":"Consequences of mutant TET2 on clonality and subclonal hierarchy","volume":"32","author":"Hirsch","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"2020030912394192500_B26","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1182\/blood-2018-01-829937","article-title":"Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A","volume":"132","author":"Buscarlet","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2020030912394192500_B27","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/sj.leu.2404754","article-title":"Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission","volume":"21","author":"van Rhenen","year":"2007","journal-title":"Leukemia"},{"issue":"2","key":"2020030912394192500_B28","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/leu.2015.252","article-title":"A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia","volume":"30","author":"Zeijlemaker","year":"2016","journal-title":"Leukemia"},{"issue":"12","key":"2020030912394192500_B29","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1182\/blood-2016-10-696054","article-title":"Biology and relevance of human acute myeloid leukemia stem cells","volume":"129","author":"Thomas","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2020030912394192500_B30","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"issue":"22","key":"2020030912394192500_B31","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1158\/0008-5472.CAN-04-1659","article-title":"C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia","volume":"64","author":"Bakker","year":"2004","journal-title":"Cancer Res"},{"issue":"7","key":"2020030912394192500_B32","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","article-title":"The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells","volume":"110","author":"van Rhenen","year":"2007","journal-title":"Blood"},{"issue":"7616","key":"2020030912394192500_B33","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nature19057","article-title":"Analysis of protein-coding genetic variation in 60,706 humans","volume":"536","author":"Lek","year":"2016","journal-title":"Nature"},{"issue":"3","key":"2020030912394192500_B34","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1474-9726.2011.00675.x","article-title":"Age-related changes in human hematopoietic stem\/progenitor cells","volume":"10","author":"Kuranda","year":"2011","journal-title":"Aging Cell"},{"issue":"12","key":"2020030912394192500_B35","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.3324\/haematol.2018.215269","article-title":"Clonal hematopoiesis and risk of acute myeloid leukemia","volume":"104","author":"Young","year":"2019","journal-title":"Haematologica"},{"issue":"7540","key":"2020030912394192500_B36","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"key":"2020030912394192500_B37","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cancergen.2018.02.006","article-title":"Mutation analysis of therapy-related myeloid neoplasms","volume":"222-223","author":"Nishiyama","year":"2018","journal-title":"Cancer Genet"},{"issue":"9","key":"2020030912394192500_B38","doi-asserted-by":"crossref","first-page":"e107587","DOI":"10.1371\/journal.pone.0107587","article-title":"Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia","volume":"9","author":"Terwijn","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"2020030912394192500_B39","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"2020030912394192500_B40","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","article-title":"PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy","volume":"23","author":"Hsu","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"11","key":"2020030912394192500_B41","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood-2018-05-850339","article-title":"PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells","volume":"132","author":"Kahn","year":"2018","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/5\/885\/1718310\/advancesadv2019001157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/5\/885\/1718310\/advancesadv2019001157.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T16:40:00Z","timestamp":1583772000000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/5\/885\/452640\/Clonal-hematopoiesis-predicts-development-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,9]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,3,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019001157","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,9]]}}}